Collegium Pharmaceutical, Inc. (COLL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 310 | 277 | 464 | 567 | 631 | 781 | 808 | 837 |
| Operating profit | $m | 187 | 159 | ||||||
| Net profit | $m | 27 | 72 | -25 | 48 | 69 | 63 | 48 | 296 |
| EPS reported | $ | 1.73 | 1.24 | ||||||
| Operating cashflow per share | $ | 10.39 | 10.16 | ||||||
| Capex per share | $ | 0.05 | 0.05 | ||||||
| FCF per share | $ | 10.33 | 10.11 | ||||||
| Free cash flow | $m | 328 | 328 | ||||||
| Net debt | $m | 530 | 723 | ||||||
| Book value equity | $m | 302 | 312 | ||||||
| Book value per share | $ | 7.60 | 9.61 | ||||||
| Number of shares | m | 39.7 | 32.46 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 26.76 | 18.25 | ||||||
| P/B LTM | x | 4.87 | 4.71 | ||||||
| P/S LTM | x | 1.88 | 1.82 | ||||||
| P/FCF LTM | x | 4.48 | 4.47 | ||||||
| EV/EBITDA LTM | x | 5.38 | 3.68 | ||||||
| EV/Sales LTM | x | 2.76 | 1.85 | ||||||
| Earnings Yield LTM | % | +3.74% | +5.48% | ||||||
| FCF Yield | % | +22.31% | +22.36% | ||||||
| Quality | |||||||||
| ROE | % | +20.84% | +15.96% | ||||||
| ROIC | % | +10.18% | +6.10% | ||||||
| Operating margin | % | +23.97% | +19.61% | ||||||
| Gross margin | % | +59.35% | +60.02% | ||||||
| FCF/Sales | % | +41.97% | +40.62% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -6.99% | -33.33% | ||||||
| Sales Growth YoY | % | +23.62% | +27.99% | ||||||
| Net Income Growth YoY | % | -9.13% | -30.75% | ||||||
| FCF Growth | % | +61.11% | +61.45% | ||||||
| Operating Profit Growth | % | +10.12% | -6.70% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.35 | 0.38 | ||||||
| Net Debt/EBITDA | x | 1.72 | 1.24 | ||||||
| EBIT/Net interest | x | 2.27 | 0.98 | ||||||
| Net debt/market cap | % | +63.79% | +1.12% | ||||||
| Net debt/Equity | x | 1.76 | 2.32 | ||||||
| Gross debt/equity | x | 3.12 | 2.75 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Collegium Pharmaceutical, Inc. (COLL)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free